格隆汇11月24日丨麒盛科技(603610.SH)公布,公司全资子公司麟盛投资（海南）有限公司拟作为有限合 伙人以自有资金9990.00万元人民币参与投资嘉兴敦盛贝贝股权投资合伙企业（有限合伙），占合伙企 业份额的99.90%。该私募基金尚在募集中，后续公司持有的基金份额如有变动，将及时履行信息披露 义务。 在确保公司主营业务发展的前提下，公司围绕智慧医疗大健康产品及服务等潜力赛道，利用专业投资机 构的投资经验，有利于进一步挖掘和布局公司在行业内的发展。同时，将有助于拓宽公司的投资渠道， 提高广大股东的投资回报。本次投资的资金来源为公司自有资金，不会影响公司生产经营活动的正常运 行，不会对公司财务及经营状况产生重大影响。本次投资完成后不会新增关联交易，也不会形成同业竞 争，不存在损害公司及全体股东利益的情形。 ...

Core Viewpoint - Qisheng Technology (603610.SH) is pursuing a long-term development strategy by exploring investment opportunities in new industries through its wholly-owned subsidiary, Linsheng Investment, which plans to invest 99.90% of its own funds, amounting to 99.90 million yuan, in Jiaxing Dunsheng Beibei Equity Investment Partnership [1] Group 1: Investment Strategy - The company aims to enhance its investment returns and asset operation capabilities by leveraging various advantageous resources through a professional investment management team [1] - Linsheng Investment will sign a partnership agreement with Hangzhou Dunjun Asset Management Co., Ltd. to facilitate this investment [1] Group 2: Investment Focus - Jiaxing Dunsheng Beibei primarily focuses on direct or indirect equity and equity-related investments to achieve good capital returns for investors [1] - The fund will concentrate on investments in smart healthcare, intelligent devices, digital health services, and other enterprises or projects with investment value and potential returns [1]

嘉兴敦盛贝贝主要通过直接或间接的股权及股权相关投资，为投资者实现良好的资本收益。敦盛贝贝重 点投资于智慧医疗、智能设备、数智健康服务等企业或项目，及其他具有投资价值和潜在回报的企业或 项目。 智通财经APP讯，麒盛科技(603610.SH)发布公告，为践行公司长远发展战略，探索投资新产业的路 径，进一步整合利用各方优势资源，通过专业化投资管理团队，提升公司资金投资收益水平和资产运作 能力，公司全资子公司麟盛投资拟与杭州敦钧资产管理有限公司(简称"杭州敦钧资产")签署合伙协议， 拟以自有资金9990万元参与投资嘉兴敦盛贝贝股权投资合伙企业(有限合伙)，占该基金总份额99.90%。 ...

Core Viewpoint - The control of Sichuang Medical Technology Co., Ltd. is set to change, with Wei Naixu's Cangnan Xinsheng becoming the controlling shareholder, transitioning from no actual controller to Wei Naixu [1][3]. Group 1: Share Transfer Agreement - The largest shareholder, Lu Nan, signed a share transfer agreement with Cangnan Xinsheng to transfer 62,739,500 shares, representing 5.61% of the total share capital, at a price of 2.872 yuan per share, totaling 180 million yuan [2][4]. - Cangnan Xinsheng will also exercise voting rights for an additional 63,890,185 shares held by Cangnan Si Jia Wulian Intelligent Partnership, representing 5.72% of the total share capital [2][3]. Group 2: Background and Previous Attempts - In April, a previous attempt was made to transfer control to Cangnan Industrial Construction Investment Co., Ltd., but this was terminated due to non-compliance with state asset supervision requirements [4]. - The company has been facing financial difficulties, with cumulative losses exceeding 2.9 billion yuan since 2021, and reported a revenue of 604 million yuan with a loss of 4.76 million yuan in the first three quarters of 2025 [4][5]. Group 3: Future Implications - The share transfer and voting rights delegation are subject to compliance review by the Shenzhen Stock Exchange and require approval from the shareholders' meeting, indicating uncertainty in the final implementation [3]. - The involvement of state-owned capital is expected to leverage resources for the long-term stable development of the company [3].

证券之星消息，根据天眼查APP于11月10日公布的信息整理，无锡紫荆智康科技有限公司天使轮融资， 融资额近亿人民币，参与投资的机构包括星连资本，英诺天使基金，尚势资本。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-10 | 星连资本 英诺天使基金 | 近亿人民币 | 天使轮 | | | 尚势资本 | | | | 2025-02-26 | 清智资本 | 未披露 | 种子轮 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 紫荆智康科技有限公司(简称"紫荆智康")成立于2024年9月，核心团队成员来自清华大学智能产业研究 院，是全球范围内领先的医疗智能体算法研究团队。公司依托的研究工作Agent Hospital通过建立疾病 产生和发展的生成模型，为医疗智能体进化提供数据飞轮，提出了医疗智能体的自我进化策略，在交互 过程中实现了医疗智能体的能力持续提升。AgentHospital在美国执业医生资格考试数据集上取得了顶尖 水平，目前已完成二十多个科室的医 ...

分红方面，思创医惠A股上市后累计派现5.32亿元。近三年，累计派现0.00元。 责任编辑：小浪快报 11月11日，思创医惠（维权）涨0.83%，成交额7641.09万元。两融数据显示，当日思创医惠获融资买入 额740.45万元，融资偿还321.91万元，融资净买入418.54万元。截至11月11日，思创医惠融资融券余额 合计1.17亿元。 资料显示，思创医惠科技股份有限公司位于浙江省杭州市滨江区月明路567号医惠中心，成立日期2003 年11月21日，上市日期2010年4月30日，公司主营业务涉及以智慧医院解决方案为核心,涉及病种科研管 理解决方案、智慧医共体解决方案、医疗健康服务运营、大数据下的人工智能服务等板块。主营业务收 入构成为：出售房产53.84%，商业智能39.28%，智慧医疗6.87%。 截至9月30日，思创医惠股东户数5.84万，较上期减少11.34%；人均流通股19077股，较上期增加 12.79%。2025年1月-9月，思创医惠实现营业收入6.04亿元，同比增长6.95%；归母净利润-476.22万元， 同比增长98.32%。 融资方面，思创医惠当日融资买入740.45万元。当前融资余额1 ...

Core Insights - The event organized by Xiamen Listed Companies Association aimed to enhance industry communication and governance experience sharing among listed companies in the region [1][4] - The study tour included visits to four notable companies, focusing on their technological innovations, market strategies, and governance practices [4] Group 1: Company Visits - The delegation visited Medtronic Medical Technology Co., Ltd., where they learned about the company's DoCare series clinical information systems, which leverage advanced mobile internet, IoT technology, and big data models to enhance competitive advantages in the healthcare sector [1] - At Jiangsu Haobio Pharmaceutical Co., Ltd., the delegation explored the company's core technologies in allergy and autoimmune testing, gaining insights into its R&D capabilities and market strategies [2] - The visit to Suzhou Maiwei Technology Co., Ltd. highlighted the company's focus on independent innovation and its breakthroughs in high-precision screen printing equipment, emphasizing its unique position in the high-end equipment sector [2] - The delegation also visited King Long United Automotive Industry (Suzhou) Co., Ltd., which is recognized as the first listed company in China's bus industry, discussing its core business, product advantages, and future market strategies [3] Group 2: Training and Discussions - The training session at Suzhou Industrial Park included discussions on China's economic outlook for 2025 and the implications of the "14th Five-Year Plan" [3] - Experts provided insights into legal practices and challenges under the new "National Nine Articles" and "Merger Six Articles," focusing on compliance and practical logic in policy implementation [3] - A deep dive into the selection and composition of boards of directors was conducted, emphasizing the importance of a scientific selection mechanism for enhancing decision-making effectiveness and transparency [4]

Group 1: Core Insights - The China International Import Expo (CIIE) serves as a platform for global companies to showcase products and understand new consumer trends in China [1][2] - Amorepacific showcased over 20 new products making their debut in China, focusing on personalized skincare solutions and addressing specific consumer needs [1][2] - The demand for health-oriented products is rising, with companies like Laiyifen integrating national health strategies into their product offerings [2][3] Group 2: Industry Trends - The expo highlighted a shift towards health-conscious consumer preferences, with products featuring low-fat, low-GI, and no additives gaining attention [2][3] - AI solutions were prominently featured, indicating a trend towards smart healthcare services that enhance patient interaction and address healthcare challenges [3][4] - Companies are transitioning from being equipment suppliers to service providers, with a focus on comprehensive AI solutions to improve healthcare efficiency and safety [4]

Core Insights - The Chinese government is set to accelerate the cultivation of application scenarios and the opening of related policy documents to promote the large-scale commercialization of new technologies and products, aiming to create a favorable innovation ecosystem [1][3] Group 1: Policy Initiatives - The State Council's recent meeting emphasized leveraging China's vast market and diverse application scenarios to prioritize new fields and high-value scenarios for innovation [1][3] - The government plans to implement demonstration actions for large-scale applications of new technologies and products, particularly in emerging industries like commercial aerospace and deep-sea technology [3][4] Group 2: Current Progress - Significant advancements in scenario-based open innovation have been made, with platforms like the National New Generation Artificial Intelligence Open Innovation Platform being established to enhance corporate innovation capabilities [2] - Emerging industries such as autonomous driving, virtual reality, and smart healthcare are witnessing the rise of new technologies and products [2] Group 3: Challenges and Recommendations - Experts highlight that scenario-based open innovation is still in its early stages, facing systemic barriers that hinder the establishment of standards and regulatory frameworks [2][4] - There is a need for effective institutional design and policy support to facilitate the development of new scenarios, ensuring a balance between innovation and regulatory safety [4]

10月31日，第138届中国进出口商品交易会(以下简称"广交会")第三期开幕，本次展会以"美好生活"为主 题，涵盖时尚、家用纺织品、玩具及孕婴童、文具、健康休闲五大板块，设立21个展区，展览面积达 51.5万平方米，设展位约2.5万个。 同时，本届广交会首次设立"智慧医疗专区"，47家聚焦智慧医疗设备产业链上游核心技术的企业同台亮 相，集中展示医疗机器人、智能诊断设备、三维数字人解剖系统等高科技产品，呈现出科技与健康融合 的生动场景。 当前我国智慧医疗在智能诊断、远程医疗、手术机器人等多个细分领域已具备先进技术水平和产业竞争 力，国内智慧医疗市场近5年年均复合增长率持续超30%。广交会顺应市场需求，依托丰富采购商资源 和培育新题材经验，搭建智慧医疗展示与贸易对接平台，助力企业对接国际标准、开拓国际市场，推动 产业升级。 在合肥中科知奇信息科技有限公司的展位上，一台巴掌大的"盒子"前围满了驻足咨询的采购商。"这是 我们的EMCG非接触式心脏健康监测仪，放床头就能实现整夜连续、高精度的心脏健康监测。"该公司 总经理张冬拿起设备向展位前的人群演示，"你们看，它通过电磁波捕捉人体信号，能及时发现如房 颤、早搏等心律失 ...